Evolution of Low-Dose Fenfluramine in the Treatment of Epileptic Encephalopathies: New Understandings of the Mechanisms, Basic Science, and Clinical Data

Date: Sunday, December 4, 2016
Time: 8:00 AM to 5:00 PM
Place: Scientific Exhibit Room 340A on Level 3 of the George R. Brown Convention Center

Poster Presentations
We cordially invite you to meet the poster presenters, members of the Zogenix clinical team, and your colleagues in a forum that focuses on the evolving basic and clinical science of the use of fenfluramine in the management of epileptic encephalopathies.

**Historical**

Preclinical

*An Examination of the Mechanism of Action of Fenfluramine in Dravet Syndrome: A Look Beyond Serotonin.* Parthena Martin, Arnold Gammaitoni, Gail Farfel, Brooks Boyd, Brad Galer (2-3 pm)*

*Fenfluramine Blocks Seizure-Induced Death in the DBA/1 Mouse Model of SUDEP.* Srinivasan Tupal, Srinivasa P. Kommajosyula, Marcus E. Randall, Carl L. Faingold (2-3 pm)*

**Preclinical**

Dravet Syndrome: Humanistic/Economic Impact

*Dravet Syndrome Hospital Utilization Rates and Costs: An Electronic Record Single-Center Cohort Study.* Jonathan D. Campbell, Melanie Whittington, Jennifer Sadlowski, Matt McCarville, Arnold Gammaitoni, Kelly Knupp (2-3 pm)*

*How Does Caring for a Child With Severe, Refractory Epilepsy Affect Lives of Caregivers? Results From Focus Groups and Interviews with Caregivers.* Dagmar Amtmann, Kendra S. Liljenquist, Fraser Bocell, Arnold R. Gammaitoni, Carey R. Aron, Bradley S. Galer, Marita Johnson, Mark P. Jensen (10-11 am)*

**Clinical**

*The Use of Pharmacokinetic Data From Adults and Allometric Scaling to Inform ZX008 (fenfluramine) Dosing for the Treatment of Dravet Syndrome in Children.* Brooks Boyd, Li Zhang, Christopher Rubino (10-11 am)*

*Effectiveness and Tolerability of Low-Dose Fenfluramine (ZX008) in Lennox-Gastaut Syndrome: A Pilot, Open-Label Dose Finding Study.* Lieven Lagae, An-Sofie Schoonjans, Arnold Gammaitoni, Brad Galer, Gail Farfel, Berten Ceulemans (2-3 pm)*

*Low-Dose Fenfluramine Significantly Reduces Seizure Frequency in Dravet Syndrome: Update of the Prospective Study.* An-Sofie Schoonjans, Fabienne Marchau, Bernard Paelinck, Boudewijn Gunning, Arnold Gammaitoni, Brad Galer, Lieven Lagae, Berten Ceulemans (10-11 am)*

*Successful Use of Fenfluramine as Add-On Treatment for Dravet Syndrome: Update of the Original Patient Cohort.* Berten Ceulemans, An-Sofie Schoonjans, Fabienne Marchau, Bernard Paelinck, Lieven Lagae (10-11 am)*

*Meet the poster authors! Authors and times they will be available are indicated in red above.*
Ask Us About Zogenix…
Zogenix, Inc, is a company committed to developing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning. Our presence at this year’s AES Annual Meeting is indicative of our dedication to finding new treatments for the ongoing challenges of epilepsy.

Learn More About the ZX008 Clinical Program in Dravet Syndrome…
Zogenix is currently conducting multicenter, double-blind, parallel-group, placebo-controlled studies to assess the efficacy, safety, and PK of ZX008 when used as adjunctive therapy for uncontrolled seizures in pediatric and young adult subjects with Dravet syndrome.

Please Visit Our Special Scientific Exhibit & Posters…
Zogenix is hosting a special scientific exhibit and poster session titled Evolution of Low-Dose Fenfluramine in the Treatment of Epileptic Encephalopathies: New Understandings of the Mechanisms, Basic Science, and Clinical Data.

The exhibit and all posters will be available all day, Sunday, December 4, 2016, from 8:00 AM to 5:00 PM in room 340A (Level 3 of the George R. Brown Convention Center). Please see the reverse side for a listing of the posters that will be showcased at this exhibit along with the presenters and the times they will be available to discuss their research.